<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586312</url>
  </required_header>
  <id_info>
    <org_study_id>TerCel004</org_study_id>
    <secondary_id>2011-005321-51</secondary_id>
    <secondary_id>EC11-309</secondary_id>
    <secondary_id>MSV_allo</secondary_id>
    <nct_id>NCT01586312</nct_id>
  </id_info>
  <brief_title>Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells</brief_title>
  <acronym>MSV_allo</acronym>
  <official_title>Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Mesenchymal Stromal Cells From Valladolid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanidad de Castilla y Leon (SACYL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Medico Teknon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC),
      obtained from bone marrow of healthy donors, for treatment of knee osteoarthritis. The trial
      is based in our own previous results with autologous MSC (ongoing NCT01183728 trial). We
      propose here a multicenter, phase I-II clinical trial, prospective, randomized, blinded, and
      controlled for the treatment of osteoarthritis (degrees II and III and IV). The assay
      consists of two arms with 15 patients each one. Patients in the experimental arm will be
      given an intra-articular transplantation of allogenic MSC, expanded &quot;Ex Vivo&quot; with our
      GMP-compliant procedure (MSV, PEI No. 10-134, authorized by the Competent Authority; same as
      in NCT01183728). In the control arm a standard treatment with intra-articular injection of
      hyaluronic acid shall be given. We shall follow the evolution of pain, disability, quality of
      life and quantitative changes in structure and composition of cartilage determined by
      T2-weighted MRI relaxation (Cartigram) for one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to one year</time_frame>
    <description>Adverse events reported. Clinical review and questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)</measure>
    <time_frame>up to one year</time_frame>
    <description>Clinical review, questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months.
WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): Questionnaire to quantify the pain, stiffness and physical function in patients with osteoarthritis of the knee or hip.
SF-12 (Short Form 12, an abbreviated form of SF36) is a questionnaire for the detection of changes in quality of life.
The visual analogue scale (VAS) is a psychometric response scale which can be used for subjective measurements of knee pain.
LEQUESNE algofunctional index: is a composite measure of pain and disability, with specific self-report questionnaires for knee (osteoarthritis).
All the scale ranges ranges (minimum and maximum scores) are between 0 and 100%.
Values are given in differences from baseline (usually negative values). More negative values show more improvement on both scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)</measure>
    <time_frame>up to one year</time_frame>
    <description>Magnetic Resonance imaging measurements of T2 relaxation (Cartigram) performed at 0, 6 and 12 months to quantify articular cartilage degeneration. The values (in milliseconds) are T1/2 for decay of the T2 MRI signals. Normal values are below 50 ms; values above 50 ms correspond to inflamed cartilage.
Mean (SD) are expressed as the number of values (of a total of 88 measurements) that are between 50 and 90 ms. A value =&lt;4.4 is considered normal (can be attained by chance). Values above 4.4 are considered pathological. The worst possible is 88.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Arthritis of Knee</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Allogenic mesenchymal stromal cells injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid (Durolane)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraarticular injection of hyaluronic acid (60 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Allogenic mesenchymal stromal cells injection</intervention_name>
    <description>Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
    <arm_group_label>Allogenic mesenchymal stromal cells injection</arm_group_label>
    <other_name>MSV</other_name>
    <other_name>Mesenchymal Stem Cells</other_name>
    <other_name>MSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
    <arm_group_label>Hyaluronic acid (Durolane)</arm_group_label>
    <other_name>Hyaluronic acid, durolane, CE mark:516407</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Knee osteoarthritis grade II, III and IV of Kellgren and Lawrence assessed by two
             observers.

          -  Chronic knee pain with mechanical characteristics.

          -  No local or systemic septic process.

          -  Haematological and biochemical analysis without significant alterations that
             contraindicate treatment.

          -  Informed written consent of the patient.

          -  The patient is able to understand the nature of the study

        Exclusion Criteria:

          -  Age over 75 or under 18 years or legally dependent

          -  Present Infection (to be included in the study no signs of infection must be
             evidenced)

          -  Congenital or acquired malformation resulting in significant deformity of the knee
             (varus&lt;10º; valgus&lt;20º) and leading to problems in application or evaluation of
             results.

          -  Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II).
             BMI estimated as mass (kg) / corporal surface (m2).

          -  Women who are pregnant or intend to become pregnant or breast-feeding

          -  Neoplasia

          -  Immunosuppressive states

          -  Intra-articular infiltartion of any treatments in the last 3 months previous to study
             inclusion

          -  Participation in another clinical trial or treatment with a different investigational
             product within 30 days prior to inclusion in the study.

          -  Other pathologic conditions or circumstances that difficult participation in the study
             according to medical criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier García-Sancho, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valladolid, Scientific Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurelio Vega, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinico Universitario, Valladolid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Orozco, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Médico Teknon, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Sanchez, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director, Cell Production Unit, Parque Científico UVa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M Moraleda, MD. PhD</last_name>
    <role>Study Director</role>
    <affiliation>Virgen de la Arrixaca University Hospital, Murcia, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Medico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.red-tercel.com</url>
    <description>Cell Therapy Network</description>
  </link>
  <link>
    <url>http://www.citospin.com</url>
    <description>MSV providing</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/mesh/68020370</url>
    <description>osteoarthritis, knee</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/mesh?term=cell%2C%20mesenchymal%20stem</url>
    <description>mesenchymal stem cells</description>
  </link>
  <reference>
    <citation>Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011 Oct 15;92(7):822-8. doi: 10.1097/TP.0b013e3182298a15.</citation>
    <PMID>21792091</PMID>
  </reference>
  <reference>
    <citation>Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentís J, Sánchez A, García-Sancho J. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013 Jun 27;95(12):1535-41. doi: 10.1097/TP.0b013e318291a2da.</citation>
    <PMID>23680930</PMID>
  </reference>
  <reference>
    <citation>Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentís J, Sánchez A, García-Sancho J. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results. Transplantation. 2014 Jun 15;97(11):e66-8. doi: 10.1097/TP.0000000000000167.</citation>
    <PMID>24887752</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <results_first_submitted>September 24, 2014</results_first_submitted>
  <results_first_submitted_qc>November 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2014</results_first_posted>
  <last_update_submitted>September 26, 2015</last_update_submitted>
  <last_update_submitted_qc>September 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee degenerative disease</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>gonarthrosis</keyword>
  <keyword>stem cell</keyword>
  <keyword>cellular therapy</keyword>
  <keyword>regenerative therapy</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>musculoskeletal Diseases</keyword>
  <keyword>Mesenchymal Stromal Cells (allogenic)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>30 patients were included between 26/Jul/2012 (Pat. 01) and12/Dic/2012 (Pat. 30).</recruitment_details>
      <pre_assignment_details>All patients fulfilled the selection criteria, were randomized and received the assigned medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Allogenic Mesenchymal Stromal Cells</title>
          <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
Injection of Mesenchymal Stromal Cells: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
        </group>
        <group group_id="P2">
          <title>Hyaluronic Acid (Durolane)</title>
          <description>Intraarticular injection of hyaluronic acid (60 mg)
Hyaluronic Acid: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allogenic Mesenchymal Stromal Cells</title>
          <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
Injection of Mesenchymal Stromal Cells: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
        </group>
        <group group_id="B2">
          <title>Hyaluronic Acid (Durolane)</title>
          <description>Intraarticular injection of hyaluronic acid (60 mg)
Hyaluronic Acid: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.60" spread="9.57"/>
                    <measurement group_id="B2" value="57.33" spread="9.41"/>
                    <measurement group_id="B3" value="56.97" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Adverse events reported. Clinical review and questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months</description>
        <time_frame>Up to one year</time_frame>
        <population>Efficacy evaluable patients (EEP): A patient has been considered evaluable whenever it has undergone the specified interventions (injection of hyaluronic acid or allogeneic MSC).
and
Safety population (SP): The population that includes all evaluable patients who have undergone one of the two study treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogenic Mesenchymal Stromal Cells</title>
            <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
Injection of Mesenchymal Stromal Cells: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
          </group>
          <group group_id="O2">
            <title>Hyaluronic Acid (Durolane)</title>
            <description>Intraarticular injection of hyaluronic acid (60 mg)
Hyaluronic Acid: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Adverse events reported. Clinical review and questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months</description>
          <population>Efficacy evaluable patients (EEP): A patient has been considered evaluable whenever it has undergone the specified interventions (injection of hyaluronic acid or allogeneic MSC).
and
Safety population (SP): The population that includes all evaluable patients who have undergone one of the two study treatments.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)</title>
        <description>Clinical review, questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months.
WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): Questionnaire to quantify the pain, stiffness and physical function in patients with osteoarthritis of the knee or hip.
SF-12 (Short Form 12, an abbreviated form of SF36) is a questionnaire for the detection of changes in quality of life.
The visual analogue scale (VAS) is a psychometric response scale which can be used for subjective measurements of knee pain.
LEQUESNE algofunctional index: is a composite measure of pain and disability, with specific self-report questionnaires for knee (osteoarthritis).
All the scale ranges ranges (minimum and maximum scores) are between 0 and 100%.
Values are given in differences from baseline (usually negative values). More negative values show more improvement on both scales.</description>
        <time_frame>up to one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogenic Mesenchymal Stromal Cells</title>
            <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
Injection of Mesenchymal Stromal Cells: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
          </group>
          <group group_id="O2">
            <title>Hyaluronic Acid (Durolane)</title>
            <description>Intraarticular injection of hyaluronic acid (60 mg)
Hyaluronic Acid: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)</title>
          <description>Clinical review, questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months.
WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): Questionnaire to quantify the pain, stiffness and physical function in patients with osteoarthritis of the knee or hip.
SF-12 (Short Form 12, an abbreviated form of SF36) is a questionnaire for the detection of changes in quality of life.
The visual analogue scale (VAS) is a psychometric response scale which can be used for subjective measurements of knee pain.
LEQUESNE algofunctional index: is a composite measure of pain and disability, with specific self-report questionnaires for knee (osteoarthritis).
All the scale ranges ranges (minimum and maximum scores) are between 0 and 100%.
Values are given in differences from baseline (usually negative values). More negative values show more improvement on both scales.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WOMAC11_Changes from Basal - General 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.48" spread="22.6"/>
                    <measurement group_id="O2" value="-4.52" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - General 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.03" spread="18.2"/>
                    <measurement group_id="O2" value="-5.47" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - General 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.47" spread="22.8"/>
                    <measurement group_id="O2" value="-4.10" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Dificulty 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.51" spread="22.8"/>
                    <measurement group_id="O2" value="-6.46" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Dificulty 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.53" spread="19.8"/>
                    <measurement group_id="O2" value="-6.97" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Dificulty 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.59" spread="23.1"/>
                    <measurement group_id="O2" value="-4.26" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Stiffness 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="30.5"/>
                    <measurement group_id="O2" value="-1.93" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Stiffness 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="23.8"/>
                    <measurement group_id="O2" value="-2.87" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Stiffness 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.67" spread="31.1"/>
                    <measurement group_id="O2" value="-4.50" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Pain 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.01" spread="23.7"/>
                    <measurement group_id="O2" value="-4.27" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Pain 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.02" spread="19.0"/>
                    <measurement group_id="O2" value="-5.97" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC11_Changes from Basal - Pain 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.30" spread="23"/>
                    <measurement group_id="O2" value="-6.36" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - General Health 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="22.5"/>
                    <measurement group_id="O2" value="0.39" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - General Health 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.64" spread="22.8"/>
                    <measurement group_id="O2" value="2.11" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - General Health 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="27.9"/>
                    <measurement group_id="O2" value="2.51" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical function 3 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="36.4"/>
                    <measurement group_id="O2" value="18.33" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical function 6 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="26.5"/>
                    <measurement group_id="O2" value="11.67" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical function 12 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.67" spread="22.9"/>
                    <measurement group_id="O2" value="20.00" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical rol 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="21.2"/>
                    <measurement group_id="O2" value="4.17" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical rol 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="38.9"/>
                    <measurement group_id="O2" value="9.17" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical rol 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="34.0"/>
                    <measurement group_id="O2" value="6.67" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Emotional rol 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="22.6"/>
                    <measurement group_id="O2" value="-5.83" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Emotional rol 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="33.0"/>
                    <measurement group_id="O2" value="1.67" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Emotional rol 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="31.0"/>
                    <measurement group_id="O2" value="0.83" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Body pain 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="26.4"/>
                    <measurement group_id="O2" value="5.00" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Body pain 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="28.0"/>
                    <measurement group_id="O2" value="11.67" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Body pain 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="36.4"/>
                    <measurement group_id="O2" value="13.33" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Mental Health 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="24.5"/>
                    <measurement group_id="O2" value="3.33" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Mental Health 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="25.2"/>
                    <measurement group_id="O2" value="3.33" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Mental Health 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="14.2"/>
                    <measurement group_id="O2" value="5.00" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Vitality 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.67" spread="37.2"/>
                    <measurement group_id="O2" value="1.67" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Vitality 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="33.4"/>
                    <measurement group_id="O2" value="1.67" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Vitality 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="36.2"/>
                    <measurement group_id="O2" value="-6.67" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Social function 3 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="27.5"/>
                    <measurement group_id="O2" value="-1.67" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Social function 6 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="27.5"/>
                    <measurement group_id="O2" value="-6.67" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Social function 12 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="29.1"/>
                    <measurement group_id="O2" value="0.00" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical Health 3 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="7.8"/>
                    <measurement group_id="O2" value="3.71" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical Health 6 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="7.0"/>
                    <measurement group_id="O2" value="3.76" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Physical Health 12 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" spread="9.3"/>
                    <measurement group_id="O2" value="4.59" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Mental Health 3 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" spread="10.5"/>
                    <measurement group_id="O2" value="-1.99" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Mental Health 6 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="11.7"/>
                    <measurement group_id="O2" value="-1.09" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12_Changes from Basal - Mental Health 12 mo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="8.2"/>
                    <measurement group_id="O2" value="-1.56" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS_Changes from Basal - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.67" spread="30.7"/>
                    <measurement group_id="O2" value="-7.53" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS_Changes from Basal - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.67" spread="29.3"/>
                    <measurement group_id="O2" value="-11.93" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS_Changes from Basal - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.20" spread="28.5"/>
                    <measurement group_id="O2" value="-13.07" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEQUESNE_Changes from Basal - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.63" spread="12.4"/>
                    <measurement group_id="O2" value="-5.18" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEQUESNE_Changes from Basal - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.95" spread="10.8"/>
                    <measurement group_id="O2" value="-5.46" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEQUESNE_Changes from Basal - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.76" spread="12.4"/>
                    <measurement group_id="O2" value="-3.13" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)</title>
        <description>Magnetic Resonance imaging measurements of T2 relaxation (Cartigram) performed at 0, 6 and 12 months to quantify articular cartilage degeneration. The values (in milliseconds) are T1/2 for decay of the T2 MRI signals. Normal values are below 50 ms; values above 50 ms correspond to inflamed cartilage.
Mean (SD) are expressed as the number of values (of a total of 88 measurements) that are between 50 and 90 ms. A value =&lt;4.4 is considered normal (can be attained by chance). Values above 4.4 are considered pathological. The worst possible is 88.</description>
        <time_frame>up to one year</time_frame>
        <population>The efficacy endpoint analysis will be based on all patients who have not committed major protocol violations, and have at least one assessment of efficacy of the end graft. 3 patients of the allogenic MSC treatment group were excluded from this analysis because of incomplete measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogenic Mesenchymal Stromal Cells</title>
            <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
Injection of Mesenchymal Stromal Cells: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
          </group>
          <group group_id="O2">
            <title>Hyaluronic Acid (Durolane)</title>
            <description>Intraarticular injection of hyaluronic acid (60 mg)
Hyaluronic Acid: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)</title>
          <description>Magnetic Resonance imaging measurements of T2 relaxation (Cartigram) performed at 0, 6 and 12 months to quantify articular cartilage degeneration. The values (in milliseconds) are T1/2 for decay of the T2 MRI signals. Normal values are below 50 ms; values above 50 ms correspond to inflamed cartilage.
Mean (SD) are expressed as the number of values (of a total of 88 measurements) that are between 50 and 90 ms. A value =&lt;4.4 is considered normal (can be attained by chance). Values above 4.4 are considered pathological. The worst possible is 88.</description>
          <population>The efficacy endpoint analysis will be based on all patients who have not committed major protocol violations, and have at least one assessment of efficacy of the end graft. 3 patients of the allogenic MSC treatment group were excluded from this analysis because of incomplete measurements.</population>
          <units>number of values (range 0-88)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRI. Nº of values between 50-90 per visit. 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.33" spread="3.5"/>
                    <measurement group_id="O2" value="13.53" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI. Nº of values between 50-90 per visit. 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" spread="4.5"/>
                    <measurement group_id="O2" value="11.73" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI.Nº of values between 50-90 per visit.12.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="5.6"/>
                    <measurement group_id="O2" value="10.73" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI. Change of Nº of measurements. 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="2.5"/>
                    <measurement group_id="O2" value="-1.80" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI. Change of Nº of measurements.12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" spread="6.0"/>
                    <measurement group_id="O2" value="-2.80" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>All patients completed the study successfully. The mean duration of the patients in the study was 12.4 (± 0.6) months, 12.5 (± 0.8) months in the MSV group and 12.4 (± 0.3) months in the hyaluronic acid group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Allogenic Mesenchymal Stromal Cells</title>
          <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
Injection of Mesenchymal Stromal Cells: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency</description>
        </group>
        <group group_id="E2">
          <title>Hyaluronic Acid (Durolane)</title>
          <description>Intraarticular injection of hyaluronic acid (60 mg)
Hyaluronic Acid: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal erosion / Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasofaringitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Artralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Artralgia/Artritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Arthralgia/Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neoplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="12" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Premature menopause</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental implant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Javier Garcia-Sancho</name_or_title>
      <organization>Instituto de Biología y Genética Molecular (IBGM)</organization>
      <phone>34 983 423 084</phone>
      <email>jgsancho@ibgm.uva.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

